Related Experiment Video
Updated: Aug 11, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Anticoagulation for prevention of stroke
1Comprehensive Stroke Program, The University of Arizona Health Sciences Center, Tucson, USA.
Insights
Warfarin significantly lowers stroke risk in atrial fibrillation (AF) patients by 70%. Risk stratification helps identify those most benefiting from anticoagulation therapy for stroke prevention.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Atrial fibrillation (AF) significantly increases stroke risk.
- Anticoagulation therapy, specifically warfarin, has emerged as a key strategy for stroke prevention in AF patients.
- Understanding risk stratification is crucial for optimizing treatment decisions.
Purpose of the Study:
- To summarize the efficacy of warfarin in reducing stroke risk for patients with atrial fibrillation.
- To highlight the role of risk factors in stratifying stroke risk within the AF population.
- To discuss the application of anticoagulation in other cardioembolic conditions.
Main Methods:
- Review of clinical evidence demonstrating warfarin's impact on stroke risk in AF.
- Analysis of stroke risk based on the presence of additional cardiovascular risk factors.
- Examination of anticoagulation's benefits in non-AF cardioembolic sources.
Main Results:
- Anticoagulation with warfarin reduces annual stroke risk in AF patients from 4.5% to 1.5% (a 70% relative risk reduction).
- Patients with risk factors like prior stroke, hypertension, heart failure, or diabetes have a significantly higher stroke risk (≥8% annually).
- Low-risk patients (under 75, no risk factors) may benefit from aspirin, while higher-risk patients gain more from anticoagulation.
Conclusions:
- Warfarin is highly effective in preventing stroke for patients with atrial fibrillation.
- Risk stratification using factors like age, hypertension, and comorbidities is essential for tailoring anticoagulation therapy.
- Anticoagulation is also beneficial for stroke prevention in other conditions with cardioembolic potential.
Abstract:
One of the important recent advances in stroke prevention is the demonstration that warfarin can substantially reduce the risk for stroke in patients with atrial fibrillation (AF). On average, patients with AF have a stroke risk of 4.5% per year. Anticoagulation reduces this to around 1.5% per year, a 70% relative risk reduction. The presence of additional risk factors, such as a recent stroke or transient ischemic attack, hypertension (particularly systolic hypertension), congestive heart failure, or diabetes, greatly increases stroke risk. Patients with any of these risk factors have a stroke risk of 8% per year or more. In contrast, patients under age 75 with none of these risk factors have a low risk for stroke (around 1% per year) when treated with aspirin. This risk stratification may help in identifying which patients with AF benefit most from anticoagulation. Anticoagulation has also been shown to prevent stroke in patients with other cardioembolic sources, including acute anterior wall myocardial infarction (particularly with echocardiographic evidence of thrombus), prosthetic heart valves, and dilated cardiomyopathies.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Coronary Artery Disease IV: Preventive Measures
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Hemorrhagic Stroke ll: Pathophysiology

